Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-751 in refractory renal cell carcinoma
NCT00073112Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of abt-751 in renal cell carcinoma (RCC), sponsored by Abbott Laboratories. Primary endpoint: Objective Response Rate at 1 year. Started Aug 2003; status: completed.
02
Drugs
abt-751
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00073112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073112.